Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CALC
CALC logo

CALC Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy CalciMedica Inc (CALC) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
0.760
1 Day change
-10.12%
52 Week Range
7.200
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

CalciMedica Inc (CALC) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock exhibits weak technical indicators, no positive trading signals, and lacks significant catalysts or financial performance data to support a buy decision. The current price trend and sentiment suggest holding off on investment until clearer opportunities arise.

Technical Analysis

The MACD is negative and expanding, indicating bearish momentum. RSI is at 28.79, which is neutral but approaching oversold territory. Moving averages are converging, showing no clear trend. Key support is at 0.779, with resistance at 0.928. The stock is trading close to its support level.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
8
Buy
6

Positive Catalysts

  • NULL identified. No recent news, no significant hedge fund or insider activity, and no recent congress trading data.

Neutral/Negative Catalysts

  • The stock has declined 10.07% in regular trading and shows a bearish technical setup. Historical and implied volatility are high, indicating uncertainty. The stock's trend analysis predicts further declines over the next day, week, and month.

Financial Performance

No financial data available for analysis. Latest quarter season data is missing.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst ratings or price target changes available for CALC.

Wall Street analysts forecast CALC stock price to rise
1 Analyst Rating
Wall Street analysts forecast CALC stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.840
sliders
Low
20
Averages
20
High
20
Current: 0.840
sliders
Low
20
Averages
20
High
20
Oppenheimer
Oppenheimer
Outperform
downgrade
$20 -> $10
AI Analysis
2026-03-05
Reason
Oppenheimer
Oppenheimer
Price Target
$20 -> $10
AI Analysis
2026-03-05
downgrade
Outperform
Reason
Oppenheimer lowered the firm's price target on CalciMedica to $10 from $20 and keeps an Outperform rating on the shares. The firm notes CalciMedica reported updates to its programs in acute kidney injury and acute pancreatitis along with quarterly financials. The most important development is the absence of any drug-related toxicity following thorough internal/external review of the unblinded Phase 2 KOURAGE dataset - as CalciMedica had indicated after voluntarily discontinuing the trial in late January.
H.C. Wainwright
H.C. Wainwright
Buy -> Neutral
downgrade
2026-01-29
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
2026-01-29
downgrade
Buy -> Neutral
Reason
H.C. Wainwright downgraded CalciMedica to Neutral from Buy without a price target. The immediate discontinuation for the Phase 2 KOURAGE clinical trial in acute kidney injury removes a major catalyst for the shares, the analyst tells investors in a research note. The firm looks to upcoming safety and population clarity as the company reviews the unblinded dataset to determine a potential path forward.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for CALC
Unlock Now

People Also Watch